Danish biotechnology company Zealand Pharma A/S (CPH:ZEAL) reported on Tuesday that pharmaceutical company Boehringer Ingelheim has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for survodutide (BI 456906) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis (stages 2 or 3).
In addition, Boehringer has initiated two Phase III clinical trials for survodutide, called LIVERAGE and LIVERAGE-Cirrhosis. These trials will evaluate the effectiveness of survodutide in treating MASH and fibrosis (scarring) in adults.
Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the glucagon and GLP-1 receptors, which are critical to controlling metabolic functions. It is licensed by Zealand Pharma to Boehringer Ingelheim, with Boehringer solely responsible for development and commercialisation globally.
Robles BioCeutics collaborates with BioCentrium
Nammi Therapeutics doses first patient in QXL138AM first in human Phase one trial (NCT06582017)
HUYABIO reveals data from phase two study assessing HBI-8000 in combination with nivolumab
Johnson & Johnson seeks approval for DARZALEX FASPRO in smoldering multiple myeloma
Bruker unveils EpicIF technology, doubling throughput in CellScape platform
Harbour BioMed submits IND application for HBM9378/SKB378 in COPD treatment
AstraZeneca's Tezspire achieves positive results in nasal polyps trial